REGENERON PHARMACEUTICALS, INC. Repayments of Convertible Debt
REGENERON PHARMACEUTICALS, INC. (REGN) reported Repayments of Convertible Debt of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2019-02-07
- REGENERON PHARMACEUTICALS, INC. repayments of convertible debt for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. repayments of convertible debt for the quarter ending 2017-09-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. repayments of convertible debt for the quarter ending 2017-06-30 was $0.00, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. repayments of convertible debt for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. repayments of convertible debt for fiscal 2018 was $0.00.
- REGENERON PHARMACEUTICALS, INC. repayments of convertible debt for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. repayments of convertible debt for fiscal 2016 was $12.90M, a 92.25% decline from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. repayments of convertible debt for fiscal 2015 was $166.47M, a 24.55% decline from fiscal 2014.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month | Repayments of Convertible Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-07 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $0.00 derived: sum of 2 quarters · filed 2019-02-07 | $0.00 derived: sum of 3 quarters · filed 2019-02-07 | $0.00 10-K · filed 2019-02-07 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2017-11-08 | $0.00 10-Q · filed 2017-11-08 | $250.00K derived: sum of 4 quarters · filed 2019-02-07 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $0.00 10-Q · filed 2017-08-03 | $250.00K derived: sum of 3 quarters · filed 2019-02-07 | $250.00K derived: sum of 4 quarters · filed 2019-02-07 | |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-04 | $250.00K derived: sum of 2 quarters · filed 2019-02-07 | $250.00K derived: sum of 3 quarters · filed 2019-02-07 | $11.16M derived: sum of 4 quarters · filed 2019-02-07 | |
| 2016-12-31 | $250.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $250.00K derived: sum of 2 quarters · filed 2019-02-07 | $11.16M derived: sum of 3 quarters · filed 2019-02-07 | $12.90M 10-K · filed 2019-02-07 | $12.89M 10-K · filed 2017-02-09 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $10.91M derived: sum of 2 quarters · filed 2017-11-08 | $12.65M 10-Q · filed 2017-11-08 | $33.11M derived: sum of 4 quarters · filed 2018-02-08 | |
| 2016-06-30 | $10.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $12.65M 10-Q · filed 2017-08-03 | $33.11M derived: sum of 3 quarters · filed 2018-02-08 | $35.12M derived: sum of 4 quarters · filed 2018-02-08 | |
| 2016-03-31 | $1.74M 10-Q · filed 2017-05-04 | $22.20M derived: sum of 2 quarters · filed 2018-02-08 | $24.20M derived: sum of 3 quarters · filed 2018-02-08 | $151.52M derived: sum of 4 quarters · filed 2018-02-08 | |
| 2015-12-31 | $20.46M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $22.47M derived: sum of 2 quarters · filed 2018-02-08 | $149.78M derived: sum of 3 quarters · filed 2018-02-08 | $166.47M 10-K · filed 2018-02-08 | |
| 2015-09-30 | $2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $129.32M derived: sum of 2 quarters · filed 2016-11-04 | $146.01M 10-Q · filed 2016-11-04 | $305.52M derived: sum of 4 quarters · filed 2017-02-09 | |
| 2015-06-30 | $127.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $144.00M 10-Q · filed 2016-08-04 | $303.51M derived: sum of 3 quarters · filed 2017-02-09 | $303.51M derived: sum of 4 quarters · filed 2017-02-09 | |
| 2015-03-31 | $16.69M 10-Q · filed 2016-05-05 | $176.20M derived: sum of 2 quarters · filed 2017-02-09 | $176.20M derived: sum of 3 quarters · filed 2017-02-09 | $237.32M derived: sum of 4 quarters · filed 2017-02-09 | |
| 2014-12-31 | $159.51M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $159.51M derived: sum of 2 quarters · filed 2017-02-09 | $220.64M derived: sum of 3 quarters · filed 2017-02-09 | $220.64M 10-K · filed 2017-02-09 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $61.13M derived: sum of 2 quarters · filed 2015-11-04 | $61.13M 10-Q · filed 2015-11-04 | $61.13M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2014-06-30 | $61.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $61.13M 10-Q · filed 2015-08-04 | $61.13M derived: sum of 3 quarters · filed 2016-02-11 | $61.13M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-07 | $0.00 derived: sum of 2 quarters · filed 2016-02-11 | $0.00 derived: sum of 3 quarters · filed 2016-02-11 | ||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $0.00 derived: sum of 2 quarters · filed 2016-02-11 | $0.00 10-K · filed 2016-02-11 | ||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $0.00 10-Q · filed 2014-11-04 | |||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-05 | ||||
| 2012-12-31 | $0.00 10-K · filed 2015-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |